CL2009002040A1 - Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis. - Google Patents
Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis.Info
- Publication number
- CL2009002040A1 CL2009002040A1 CL2009002040A CL2009002040A CL2009002040A1 CL 2009002040 A1 CL2009002040 A1 CL 2009002040A1 CL 2009002040 A CL2009002040 A CL 2009002040A CL 2009002040 A CL2009002040 A CL 2009002040A CL 2009002040 A1 CL2009002040 A1 CL 2009002040A1
- Authority
- CL
- Chile
- Prior art keywords
- thrombosis
- quinazolin
- thiophen
- dioxo
- methylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea; formas cristalinas de dichas sales; método de preparación; composición farmacéutica, útil para prevenir o tratar trombosis y condiciones patológicas relacionadas con trombosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/265,699 US20090156620A1 (en) | 2007-05-02 | 2008-11-05 | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009002040A1 true CL2009002040A1 (es) | 2010-09-10 |
Family
ID=41460405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009002040A CL2009002040A1 (es) | 2008-11-05 | 2009-11-05 | Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis. |
Country Status (14)
Country | Link |
---|---|
US (2) | US20090156620A1 (es) |
EP (1) | EP2358706A1 (es) |
JP (1) | JP2012508243A (es) |
KR (1) | KR20110093843A (es) |
CN (1) | CN102272130A (es) |
AR (1) | AR075097A1 (es) |
AU (1) | AU2009313565A1 (es) |
BR (1) | BRPI0921649A2 (es) |
CA (1) | CA2742601A1 (es) |
CL (1) | CL2009002040A1 (es) |
MX (1) | MX2011004841A (es) |
RU (1) | RU2011122385A (es) |
TW (1) | TW201022252A (es) |
WO (1) | WO2010054020A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1951254E (pt) * | 2005-11-03 | 2012-04-12 | Portola Pharm Inc | [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas |
CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
JP2013544271A (ja) * | 2010-12-03 | 2013-12-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 式(i)の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法 |
CN103288761B (zh) * | 2012-02-25 | 2017-08-11 | 浙江华海药业股份有限公司 | 一种合成1,2,3,4‑喹唑啉‑2,4‑二酮衍生物的新方法 |
AU2017364349A1 (en) * | 2016-11-28 | 2019-07-11 | Sarin PARAYIL | Novel organic crystalline salt of haloacetic acid |
CN115490643A (zh) * | 2022-11-21 | 2022-12-20 | 南京合创药业有限公司 | 一种一锅法合成3-二氯苯基-6-氟-2,4(1h,3h)-喹唑啉二酮的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
PT1951254E (pt) * | 2005-11-03 | 2012-04-12 | Portola Pharm Inc | [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas |
CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
WO2008137753A2 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
-
2008
- 2008-11-05 US US12/265,699 patent/US20090156620A1/en not_active Abandoned
-
2009
- 2009-11-04 BR BRPI0921649A patent/BRPI0921649A2/pt not_active Application Discontinuation
- 2009-11-04 WO PCT/US2009/063313 patent/WO2010054020A1/en active Application Filing
- 2009-11-04 AU AU2009313565A patent/AU2009313565A1/en not_active Abandoned
- 2009-11-04 EP EP09744901A patent/EP2358706A1/en not_active Withdrawn
- 2009-11-04 CN CN2009801536367A patent/CN102272130A/zh active Pending
- 2009-11-04 AR ARP090104261A patent/AR075097A1/es unknown
- 2009-11-04 MX MX2011004841A patent/MX2011004841A/es not_active Application Discontinuation
- 2009-11-04 TW TW098137421A patent/TW201022252A/zh unknown
- 2009-11-04 CA CA2742601A patent/CA2742601A1/en not_active Abandoned
- 2009-11-04 JP JP2011535655A patent/JP2012508243A/ja active Pending
- 2009-11-04 RU RU2011122385/04A patent/RU2011122385A/ru unknown
- 2009-11-04 KR KR1020117012777A patent/KR20110093843A/ko not_active Application Discontinuation
- 2009-11-05 CL CL2009002040A patent/CL2009002040A1/es unknown
-
2011
- 2011-06-22 US US13/166,763 patent/US20120129876A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201022252A (en) | 2010-06-16 |
BRPI0921649A2 (pt) | 2016-02-10 |
CA2742601A1 (en) | 2010-05-14 |
EP2358706A1 (en) | 2011-08-24 |
JP2012508243A (ja) | 2012-04-05 |
WO2010054020A1 (en) | 2010-05-14 |
AR075097A1 (es) | 2011-03-09 |
AU2009313565A1 (en) | 2010-05-14 |
US20090156620A1 (en) | 2009-06-18 |
MX2011004841A (es) | 2011-07-28 |
CN102272130A (zh) | 2011-12-07 |
RU2011122385A (ru) | 2012-12-20 |
KR20110093843A (ko) | 2011-08-18 |
US20120129876A1 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009002040A1 (es) | Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis. | |
CY1124208T1 (el) | Αλατα η συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης | |
CL2009000316A1 (es) | Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos. | |
BRPI0821688A2 (pt) | mistura para o tratamento de fertilizantes contendo uréia | |
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BRPI0918586A2 (pt) | compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico | |
WO2016105525A3 (en) | Novel pyrimidines as egfr inhibitors and methods of treating disorders | |
GT201200181A (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas | |
EA201100094A1 (ru) | Тиадиазолилоксифениламидины и их применение в качестве фунгицидов | |
EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
BRPI0916593A2 (pt) | processo para modificação contínua de gesso diidratado e gesso diidratado modificado obtido através do processo. | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
CL2009001484A1 (es) | Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia. | |
BRPI0906786A2 (pt) | Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit. | |
CL2014000076A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de la enzima dipeptidilpeptidasa iv (dpp-iv); proceso para prepararlos; sal de los compuestos; compuestos intermediarios; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y su uso para tratar diabetes mellitus tipo ii u obesidad. | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
CL2012001348A1 (es) | Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. | |
BRPI0906805A2 (pt) | Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação | |
BRPI0810076A2 (pt) | Processo para preparar compostos, uso de compostos, composto, e mistura. | |
BRPI0919876A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. | |
UY33917A (es) | ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?. | |
BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
BR112012007241A2 (pt) | compostos , composição farmacêutica, método para tratar desordens, uso dos compostos, medicamento, método para selecionar inibidores com pequenas moléculas de pcsk9 e pequenas moléculas | |
BRPI0913173A2 (pt) | "aditivo para inibição de corrosão causada por ácido e método de produção e uso do mesmo" | |
CL2007002837A1 (es) | Uso de fenitoina para tratar mucositis oral. |